The Johns Hopkins University spinout’s latest funding will go toward further developing its lead candidate, VTA-110, for muscular dystrophy treatments.

Vita Therapeutics, a US-based cell engineering spinout of Johns Hopkins University, has secured $20m in a round led by ageing research group Cambrian Biopharma, Baltimore Business Journal has reported. Founded in 2019, Vita is working on stem cells that can contribute to muscle regeneration in patients suffering from muscular dystrophy – a type of genetic…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.